Follow the people · Insider
Robin Shane Readnour
Robin Shane Readnour files insider transactions with the SEC as a director of AN2 Therapeutics (ANTX). We hold 3 disclosed purchases and sales filed since 31 March 2022, 3 of them in the last 90 days.
- Files forANTX
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure8 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 29 March 2022 — 8 September 2026Director · AN2 Therapeutics (ANTX)49 Form 4 lines · source: SEC Form 4
Everything they disclosed
49 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 2,877 shares of AN2 TherapeuticsSEC Form 48 September 2026Common Stock · traded 3 September 2026 · filed 8 September 2026
- ▼ sold on the open market 3,223 shares of AN2 TherapeuticsSEC Form 48 September 2026Common Stock · traded 3 September 2026 · filed 8 September 2026
- ▼ sold on the open market 4,725 shares of AN2 TherapeuticsSEC Form 48 September 2026Common Stock · traded 8 September 2026 · filed 8 September 2026
- ▼ sold on the open market 5,294 shares of AN2 TherapeuticsSEC Form 48 September 2026Common Stock · traded 8 September 2026 · filed 8 September 2026
- ▼ sold on the open market 16,696 shares of AN2 TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 18,706 shares of AN2 TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- was granted 20,724 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- returned to the issuer 20,724 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- was granted 23,742 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- was granted 20,724 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- returned to the issuer 20,724 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- was granted 23,742 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- returned to the issuer 23,742 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- returned to the issuer 23,742 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 March 2026Stock Option (right to buy) · traded 19 March 2026 · filed 23 March 2026
- was granted 20,400 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 February 2026Stock Option (Right to Buy) · traded 20 February 2026 · filed 23 February 2026
- was granted 20,400 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 February 2026Stock Option (Right to Buy) · traded 20 February 2026 · filed 23 February 2026
- was granted 19,111 shares of AN2 Therapeutics (a derivative holding)SEC Form 423 May 2025Stock Option (Right to Buy) · traded 22 May 2025 · filed 23 May 2025
- was granted 9,077 shares of AN2 TherapeuticsSEC Form 423 December 2024Common Stock · traded 19 December 2024 · filed 23 December 2024
- ▲ bought on the open market 12,711 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 6 December 2024 · filed 10 December 2024
- ▲ bought on the open market 6,517 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 6 December 2024 · filed 10 December 2024
- ▲ bought on the open market 12,289 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 9 December 2024 · filed 10 December 2024
- ▲ bought on the open market 18,483 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 9 December 2024 · filed 10 December 2024
- ▲ bought on the open market 5,000 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 10 December 2024 · filed 10 December 2024
- ▲ bought on the open market 5,000 shares of AN2 TherapeuticsSEC Form 410 December 2024Common Stock · traded 10 December 2024 · filed 10 December 2024
- ▲ bought on the open market 12,500 shares of AN2 TherapeuticsSEC Form 427 November 2024Common Stock · traded 26 November 2024 · filed 27 November 2024
- ▲ bought on the open market 12,500 shares of AN2 TherapeuticsSEC Form 427 November 2024Common Stock · traded 26 November 2024 · filed 27 November 2024
- ▲ bought on the open market 25,000 shares of AN2 TherapeuticsSEC Form 427 November 2024Common Stock · traded 27 November 2024 · filed 27 November 2024
- ▲ bought on the open market 25,000 shares of AN2 TherapeuticsSEC Form 427 November 2024Common Stock · traded 27 November 2024 · filed 27 November 2024
- ▲ bought on the open market 75,000 shares of AN2 TherapeuticsSEC Form 421 November 2024Common Stock · traded 19 November 2024 · filed 21 November 2024
- ▲ bought on the open market 75,000 shares of AN2 TherapeuticsSEC Form 421 November 2024Common Stock · traded 19 November 2024 · filed 21 November 2024
- ▲ bought on the open market 25,000 shares of AN2 TherapeuticsSEC Form 421 November 2024Common Stock · traded 20 November 2024 · filed 21 November 2024
- ▲ bought on the open market 25,000 shares of AN2 TherapeuticsSEC Form 421 November 2024Common Stock · traded 20 November 2024 · filed 21 November 2024
- was granted 64,503 shares of AN2 Therapeutics (a derivative holding)SEC Form 421 June 2024Stock Option (Right to Buy) · traded 19 June 2024 · filed 21 June 2024
- ▼ sold on the open market 706 shares of AN2 TherapeuticsSEC Form 417 January 2024Common Stock · traded 12 January 2024 · filed 17 January 2024
- ▼ sold on the open market 719 shares of AN2 TherapeuticsSEC Form 417 January 2024Common Stock · traded 12 January 2024 · filed 17 January 2024
- ▼ sold on the open market 1,869 shares of AN2 TherapeuticsSEC Form 412 January 2024Common Stock · traded 10 January 2024 · filed 12 January 2024
- ▼ sold on the open market 1,800 shares of AN2 TherapeuticsSEC Form 412 January 2024Common Stock · traded 10 January 2024 · filed 12 January 2024
- was granted 23,742 shares of AN2 Therapeutics (a derivative holding)SEC Form 49 June 2023Stock Option (right to buy) · traded 7 June 2023 · filed 9 June 2023
- was granted 20,724 shares of AN2 Therapeutics (a derivative holding)SEC Form 416 May 2022Stock Option (right to buy) · traded 12 May 2022 · filed 16 May 2022
- converted 285,156 shares of AN2 Therapeutics (a derivative holding)SEC Form 431 March 2022Series A Convertible Preferred Stock · traded 29 March 2022 · filed 31 March 2022
- converted 333,135 shares of AN2 Therapeutics (a derivative holding)SEC Form 431 March 2022Series A Convertible Preferred Stock · traded 29 March 2022 · filed 31 March 2022
- converted 61,491 shares of AN2 Therapeutics (a derivative holding)SEC Form 431 March 2022Series B Convertible Preferred Stock · traded 29 March 2022 · filed 31 March 2022
- converted 71,839 shares of AN2 Therapeutics (a derivative holding)SEC Form 431 March 2022Series B Convertible Preferred Stock · traded 29 March 2022 · filed 31 March 2022
- converted 285,156 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- converted 333,135 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- converted 61,491 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- converted 71,839 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- ▲ bought on the open market 70,716 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- ▲ bought on the open market 82,618 shares of AN2 TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.